Evidence map›Paper›PMID 26377476›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2015

Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.

Jonathan M Ehrich, Daniel I Messinger, Cerise R Knakal, Jamie R Kuhar, Selena S Schattauer, Michael R Bruchas, Larry S Zweifel, Brigitte L Kieffer, Paul E M Phillips, Charles Chavkin

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 193 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Kappa opioid receptor control of motivated behavior revisited.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  12. Nalfurafine is Aversive at Antinociceptive Doses in Mice.Pharmacology research & perspectives · 2025
    Article
  13. Article
  14. Kappa Opioid Receptors Control a Stress-Sensitive Brain Circuit and Drive Cocaine Seeking.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Jonathan M EhrichGraduate Program in Neurobiology and Behavior, Department of Pharmacology, and.
Daniel I MessingerDepartment of Pharmacology, and.
Cerise R KnakalDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, and.
Jamie R KuharDepartment of Pharmacology, and.
Selena S SchattauerDepartment of Pharmacology, and.
Michael R BruchasDepartment of Pharmacology, and.
Larry S ZweifelGraduate Program in Neurobiology and Behavior, Department of Pharmacology, and Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, and.
Brigitte L KiefferInstitut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale/Université de Strasbourg, Illkirch, France.
Paul E M PhillipsGraduate Program in Neurobiology and Behavior, Department of Pharmacology, and Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, and.
Charles ChavkinGraduate Program in Neurobiology and Behavior, Department of Pharmacology, and cchavkin@uw.edu.
Institute of Pharmacology · CZBehavioral Tech Research, Inc. · USInserm · FR

Funding

TRAINING IN THE MOLECULAR PHARMACOLOGY OF ABUSED DRUGST32DA007278 · NIDA · UNIVERSITY OF WASHINGTON · PI Susan Marie Ferguson, Paul E. M. Phillips · 1993 to 2026
$9.8M
p38 MAPK Mechanisms of Kappa Opioid-Induced BehaviorsR01DA030074 · NIDA · UNIVERSITY OF WASHINGTON · PI CHAVKIN, CHARLES · 2011 to 2020
$3.2M
Development of cGMP Manufacturing Process for CBDR44DA038932 · NIDA · APHIOS CORPORATION · PI CASTOR, TREVOR P. · 2014 to 2016
$1.7M
Dynorphins and Kappa Opioid Receptors in the Stress ResponseK05DA020570 · NIDA · UNIVERSITY OF WASHINGTON · PI CHAVKIN, CHARLES · 2006 to 2015
$1.2M
Opioid and Noradrenergic Mechanisms in Stress and Drug SeekingK99DA025182 · NIDA · UNIVERSITY OF WASHINGTON · PI BRUCHAS, MICHAEL R. · 2009 to 2010
$298k
NIDA NIH HHS F31DA038932NIDA NIH HHS K05 DA020570NIDA NIH HHS K05DA020570NIDA NIH HHS K99 DA025182NIDA NIH HHS K99DA025182NIDA NIH HHS R01 DA030074NIDA NIH HHS R01DA030074NIDA NIH HHS R44 DA038932NIDA NIH HHS T32 DA007278NIDA NIH HHS T32DA07278
6 · The paper itself

Abstract

The endogenous dynorphin-κ opioid receptor (KOR) system encodes the dysphoric component of the stress response and controls the risk of depression-like and addiction behaviors; however, the molecular and neural circuit mechanisms are not understood. In this study, we report that KOR activation of p38α MAPK in ventral tegmental (VTA) dopaminergic neurons was required for conditioned place aversion (CPA) in mice. Conditional genetic deletion of floxed KOR or floxed p38α MAPK by Cre recombinase expression in dopaminergic neurons blocked place aversion to the KOR agonist U50,488. Selective viral rescue by wild-type KOR expression in dopaminergic neurons of KOR(-/-) mice restored U50,488-CPA, whereas expression of a mutated form of KOR that could not initiate p38α MAPK activation did not. Surprisingly, while p38α MAPK inactivation blocked U50,488-CPA, p38α MAPK was not required for KOR inhibition of evoked dopamine release measured by fast scan cyclic voltammetry in the nucleus accumbens. In contrast, KOR activation acutely inhibited VTA dopaminergic neuron firing, and repeated exposure attenuated the opioid response. This adaptation to repeated exposure was blocked by conditional deletion of p38α MAPK, which also blocked KOR-induced tyrosine phosphorylation of the inwardly rectifying potassium channel (GIRK) subunit Kir3.1 in VTA dopaminergic neurons. Consistent with the reduced response, GIRK phosphorylation at this amino terminal tyrosine residue (Y12) enhances channel deactivation. Thus, contrary to prevailing expectations, these results suggest that κ opioid-induced aversion requires regulation of VTA dopaminergic neuron somatic excitability through a p38α MAPK effect on GIRK deactivation kinetics rather than by presynaptically inhibiting dopamine release. SIGNIFICANCE STATEMENT: Kappa opioid receptor (KOR) agonists have the potential to be effective, nonaddictive analgesics, but their therapeutic utility is greatly limited by adverse effects on mood. Understanding how KOR activation produces dysphoria is key to the development of better analgesics and to defining how the endogenous dynorphin opioids produce their depression-like effects. Results in this study show that the aversive effects of κ receptor activation required arrestin-dependent p38α MAPK activation in dopamine neurons but did not require inhibition of dopamine release in the nucleus accumbens. Thus, contrary to the prevailing view, inhibition of mesolimbic dopamine release does not mediate the aversive effects of KOR activation and functionally selective κ opioids that do not activate arrestin signaling may be effective analgesics lacking dysphoric effects.

Indexed as

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAction PotentialsAnalgesics, Non-NarcoticAnimalsAvoidance LearningConditioning, ClassicalDopamineDopaminergic NeuronsEnzyme ActivationGene Knockdown TechniquesG Protein-Coupled Inwardly-Rectifying Potassium ChannelsIon Channel GatingMaleMAP Kinase Signaling SystemMiceMice, Inbred C57BL3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAnalgesics, Non-NarcoticDopamineG Protein-Coupled Inwardly-Rectifying Potassium Channelsp38 Mitogen-Activated Protein KinasesPotassiumReceptors, Opioid, kappaRecombinant Fusion ProteinsdepressiondopaminedynorphinGIRKkappa opioid receptorstress

Identifiers

PMID26377476
PMCPMC4571610
OpenAlexW1409281047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.